| Literature DB >> 28923280 |
Nishi Kumari1, Patrick William Jaynes2, Azad Saei3, Prasanna Vasudevan Iyengar2, John Lalith Charles Richard2, Pieter Johan Adam Eichhorn4.
Abstract
The initial experiments performed by Rose, Hershko, and Ciechanover describing the identification of a specific degradation signal in short-lived proteins paved the way to the discovery of the ubiquitin mediated regulation of numerous physiological functions required for cellular homeostasis. Since their discovery of ubiquitin and ubiquitin function over 30years ago it has become wholly apparent that ubiquitin and their respective ubiquitin modifying enzymes are key players in tumorigenesis. The human genome encodes approximately 600 putative E3 ligases and 80 deubiquitinating enzymes and in the majority of cases these enzymes exhibit specificity in sustaining either pro-tumorigenic or tumour repressive responses. In this review, we highlight the known oncogenic and tumour suppressive effects of ubiquitin modifying enzymes in cancer relevant pathways with specific focus on PI3K, MAPK, TGFβ, WNT, and YAP pathways. Moreover, we discuss the capacity of targeting DUBs as a novel anticancer therapeutic strategy.Entities:
Keywords: Cancer; Deubiquitinating enzymes; Dub inhibitors; E3 ligases; Ubiquitin
Mesh:
Substances:
Year: 2017 PMID: 28923280 DOI: 10.1016/j.bbcan.2017.09.002
Source DB: PubMed Journal: Biochim Biophys Acta Rev Cancer ISSN: 0304-419X Impact factor: 10.680